ILCA 2023 | Exploration of Immunotherapy as Neoadjuvant Treatment in Reducing Postoperative Recurrence of HCC
Immune checkpoint inhibitors (ICIs) have been widely used in the clinical treatment of patients with advanced hepatocellular carcinoma (HCC), significantly improving their survival. While early-stage HCC can be cured with hepatectomy, up to 70% of patients may experience tumor recurrence within two years post-surgery. Therefore, the feasibility of perioperative ICI use to effectively inhibit tumor recurrence and further improve the postoperative survival rate of HCC patients is a subject that needs further exploration. From September 7th-9th, 2023, the global academic feast in the field of liver cancer—the 17th International Liver Cancer Association (ILCA) annual meeting was held grandly in Amsterdam, the capital of the Netherlands. Dr. Antonio D'Alessio from Imperial College London presented the PRIME-HCC study, a clinical trial of ICIs as a neoadjuvant treatment in unresectable HCC patients (Abstract number: O-13). This attracted wide attention from attendees, and Dr. Antonio D'Alessio was awarded the "Young Investigator" medal by the ILCA conference. Here's a comprehensive report.
